Pharmaceuticals Italy

Italy Exosome Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Italy Exosome Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Application, Source, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Italy · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $6.1 Mn Placeholder estimate
Estimate 2025 $7.6 Mn 2.4% of the global market
Projected 2034 $54.6 Mn 618.7% Adds $47.0 Mn over 9 forecast years
CAGR 2025–2034 24.5% Faster than 94% of 180 Pharmaceuticals markets here
Key players 5 Companies profiled
  • Italy is 2.43% of the global market.
  • In Europe, the largest is Germany at $12.1 Mn.
  • Fastest growing: Russia at 25.2% a year.
  • Italy ranks 3rd of 6 by size in Europe.

Market size projection

Italy

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$47.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Exosome Therapeutics Market market size by year, Italy
YearMarket sizeChange that yearSince 2025
2024 (estimate) $6.1 Mn — —
2025 (base) $7.6 Mn +$1.5 Mn —
2026 (forecast) $9.5 Mn +$1.9 Mn +24.5%
2027 (forecast) $11.8 Mn +$2.3 Mn +55%
2028 (forecast) $14.7 Mn +$2.9 Mn +93%
2029 (forecast) $18.2 Mn +$3.6 Mn +140.3%
2030 (forecast) $22.7 Mn +$4.5 Mn +199.1%
2031 (forecast) $28.3 Mn +$5.6 Mn +272.4%
2032 (forecast) $35.2 Mn +$6.9 Mn +363.6%
2033 (forecast) $43.8 Mn +$8.6 Mn +477.2%
2034 (forecast) $54.6 Mn +$10.7 Mn +618.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Italy Exosome Therapeutics Market Analysis at a glance
Market size, 2025$7.6 Mn placeholder estimate
Forecast, 2034$54.6 Mn placeholder estimate
Growth (CAGR), 2025–203424.5% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsApplication, source and end user (see all)
Key playersCodiak BioSciences, Evox Therapeutics, Aegle Therapeutics, Capricor Therapeutics, ExoCoBio, Inc (see all)
Regulator in ItalyAIFASource: Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
Active clinical trials5 in ItalySource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Italy Exosome Therapeutics Market Analysis Executive Summary

Exosome therapeutics use tiny vesicles released by cells to carry drugs or healing signals, for cancer, inflammation and regenerative medicine.

Key segments of the exosome Therapeutics market include application (Drug Delivery, Regenerative Medicine and Diagnostics) and source (Stem Cell-Derived, Plant-Derived and Engineered).

Bar chart: Italy Exosome Therapeutics market size, 2024–2034, placeholder estimates. $6.1 Mn in 2024, $7.6 Mn in 2025 and $54.6 Mn in 2034, 24.5% CAGR.
Italy Exosome Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Italy Exosome Therapeutics Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the exosome Therapeutics market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the exosome Therapeutics market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the exosome Therapeutics market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Exosome Therapeutics Market in Italy

The exosome Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Exosome Therapeutics Market in Italy

Exosome Therapeutics in Italy: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AIFA, the Italian Medicines Agency, which also negotiates prices and reimbursement.⁠[1] The National Health Service (SSN), run by the regions, gives universal cover, and AIFA decides which medicines it pays for.⁠[2] ClinicalTrials.gov lists 5 studies on Exosome Therapeutics that are recruiting, active or about to start in Italy.⁠[3]

[1] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.

[2] Italian Ministry of Health. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for exosome Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Italy.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Exosome Therapeutics right now, from free public sources.

Clinical trials

5 active trials in Italy

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Biocells Medical 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Exosome Therapeutics in context

Italy compared

  • Health spending per person: 3,398 US$ per person (2024). World: 1,317 US$ per person (2023). 4th highest of the 6 countries we cover in Europe.[1]
  • Doctors: 4.19 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 4th highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 25.1% of people (2025). World: 10.4% of people (2025). Highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Exosome Therapeutics market in Italy?
Placeholder estimate: about $7.6 Mn in 2025, rising to about $54.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Exosome Therapeutics market in Italy growing?
Placeholder estimate: about 24.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Exosome Therapeutics market report cover?
The report splits the market by application (Drug Delivery, Regenerative Medicine, Diagnostics, Oncology), source (Stem Cell-Derived, Plant-Derived, Engineered) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Exosome Therapeutics market?
Key players include Codiak BioSciences, Evox Therapeutics, Aegle Therapeutics, Capricor Therapeutics and ExoCoBio, Inc.
What is driving the Exosome Therapeutics market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the exosome Therapeutics market.
Who regulates Exosome Therapeutics in Italy?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AIFA, the Italian Medicines Agency, which also negotiates prices and reimbursement. Source: Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
How is healthcare paid for in Italy?
The National Health Service (SSN), run by the regions, gives universal cover, and AIFA decides which medicines it pays for. Source: Italian Ministry of Health. Checked 14 Nov 2026.
How many clinical trials on Exosome Therapeutics are running in Italy?
5 studies are recruiting, active or about to start in Italy, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.
How much research is published on Exosome Therapeutics?
PubMed lists 29 papers on Exosome Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Italy

See all

Related on biologics and biosimilars and genomics

See the topic